Alector (ALEC) Asset Writedowns and Impairment (2019 - 2025)
Alector's (ALEC) quarterly Asset Writedowns and Impairment came in at $1.8 million in Q4 2025, down 19.68% quarter-over-quarter from $2.2 million in Q3 2024.
Powered by 
Analysis
Alector (ALEC) Asset Writedowns and Impairment (2019 - 2025) Analysis & Trends
Alector (ALEC) has reported Asset Writedowns and Impairment for 3 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $1.8 million in Q4 2025; TTM through Dec 2025 was $4.0 million, a 80.32% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, up 32.52% from the prior year.
- Asset Writedowns and Impairment was $1.8 million for Q4 2025 at Alector, down from $2.2 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $2.2 million in Q3 2024 and troughed at $1.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2024 | 2.21 Mn |
| Dec 31, 2019 | 42,000.00 |